San Diego-dependent Viking Therapeutics marked by itself as a significant competitor during the weight loss drug industry in February after revealing promising details from the mid-phase trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when provided being a weekly injection As well as in March t